A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

NCT01717326 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

573

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Grazoprevir
DRUG: Elbasvir
DRUG: Placebo to Elbasvir
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC